Good-bye CRRT, here comes SLED? ... not so fast!
Crit Care. 2012 Nov 5;16(6):167
Authors: Joannidis M
ABSTRACT: In the continuing dispute about the superiority of either intermittent or continuous renal replacement therapy for the critically ill, hybrid methods such as sustained low-efficiency dialysis (SLED) combining the advantages of both modalities - that is, excellent hemodynamic stability and low costs - receive growing attention. The study by Schwenger and colleagues is the first randomized trial indicating that there may be no significant difference in survival at 90 days between patients treated with SLED as compared with those treated with continuous veno-venous hemofiltration.
PMID: 23148709 [PubMed - as supplied by publisher]